Latest updates for Bx:ca
Fresh curated links around BX:CA are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- TMX Group Limited (X:CA) Middlebury Holdings Pty Limited, Cboe Canada Inc - M&A Call - Slideshow
- Brookfield renews normal course issuer bid
- Market Digest: BMY, SWX
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Barrick Mining Corp (B): Outperform Rating Amid Global Gold Expansion
Extendicare Inc. (EXE:CA) Shareholder/Analyst Call - Slideshow
RB Global expects 2026 GTV growth of 6%-9% while BigIron closing targeted for Q2
Bicara (BCAX) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DateMay 11, 2026, at 8:30 a.m. ETCall participantsChief Executive Officer — Claire Mazumdar ClemonChief Medical Officer — Bill SchelmanChief Commerc...
Bank of Montreal (BMO:CA) Shareholder/Analyst Call Transcript
Xtract One Files Final Base Shelf Prospectus
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO...
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Brixmor Property Group Inc. (BRX) Shareholder/Analyst Call Transcript
Hudbay Minerals Inc. (HBM:CA) Shareholder/Analyst Call Transcript
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders
Bausch + Lomb Corporation (BLCO): Carl C. Icahn Likes This Stock
Boston Scientific Corporation (BSX): Billionaire Tom Steyer Is Loading Up on This Stock
Extendicare Inc. (EXE:CA) Shareholder/Analyst Call Transcript
Boston Scientific: From Hypergrowth To Durable Compounding
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.